Enhancement of Spontaneous Fibrinolytic Activity in Diabetic Retinopathy

Summary

The fibrinolytic system was studied in 96 patients with type I diabetes mellitus. Patients were grouped according to their degree of retinopathy; 38 patients with no evidence of retinopathy, 28 patients with background retinopathy and 30 patients with proliferative retinopathy. Thirty healthy individuals served as controls. The basal fibrinolytic activity as measured by clot lysis time and t-PA activity was increased in diabetic patients. This was associated with low levels of plasminogen activator inhibitor. Increased levels of D-dimer in diabetic patients further indicate enhanced in vivo fibrinolysis. The increase in fibrinolytic activity was highest in diabetics without retinopathy, and decreased with increasing retinopathy. Endothelial release of t-PA after venous occlusion was not different between controls and all diabetic groups. These findings suggest that in type I diabetics the fibrinolytic system is in an activated state. With worsening of retinopathy this increase in fibrinolytic activity diminishes.

• REFERENCES

• 1 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244-249
• 2 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360
• 3 Merimee TJ. Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990; 322: 978-983
• 4 Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989; 38: 1203-1206
• 5 Christe M, Fritschi J, Lämmle B, Trah TH, Marbet GA, Berger W, Duckert F. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 138-142
• 6 Tschöpe D, Roesen P, Kaufmann L. et al Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 595-599
• 7 Mustard JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med 1984; 311: 665-667
• 8 Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus. Diabetes 1991; 40: 653-659
• 9 Ostermann H, van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 1986; 16: 385-416
• 10 Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: Evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha₂-plasmin inhibitor complex. Thromb Res. 1989; 55: 727-735
• 11 Small M, Kluft C, MacCuish AC, Lowe GDO. Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 1989; 12: 655-658
• 12 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates: Chemical and Clinical Usage.. Scully MF, Kakkar VV. (eds) Churchill Livingstone, Edinburgh: 1979. pp 128-139
• 13 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new, rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
• 14 Blix S. Studies on the fibrinolytic system in the euglobulin fraction of human plasma. Scand J Clin Lab Invest 1961; 13 (Suppl58): 03-19
• 15 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 16 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
• 17 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 18 Amiral J, Plassart V, Minard F. Measurement and clinical relevance of D-Dimer by ELISA. In: Fibrinogen and Its Derivatives.. Müller-Berghaus G, Scheefers-Borchel U, Selmyr E, Henschen A. (eds) Excerpta Medica, Amsterdam: 1986. pp 285-290
• 19 Bern MM, Cassani MP, Horton J, Rand L, Davis G. Changes of fibrinolysis and factor VIII coagulant, antigen and ristocetin cofactor in diabetes mellitus and atherosclerosis. Thromb Res 1980; 19: 831-839
• 20 Sharma SC. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile-onset and maturity-onset diabetes mellitus. J Clin Pathol 1981; 34: 501-503
• 21 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; ii: 964-966
• 22 Knaap JHvd, de Boer AC, Pannebakker MAG, van Heerde W, den Ottolander GJH. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP. Thromb Haemostas 1985; 53: 118-121
• 23 Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72
• 24 Alessi MC, Juhan-Vague I, Kooistra T, Declerk PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
• 25 Juhan-Vague I, Vague P, Alessi MC. et al Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331-336
• 26 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F. Shortterm infusion of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516
• 27 Van Loon BJP, Debart ACW, Radder JK, Frolich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4: 93-94
• 28 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 29 Marongui F, Conti M, Mameli G, Sorano GG, Cossu E, Cirillo R, Balestrieri A. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity? Thromb Res. 1990; 58: 91-99
• 30 Tsianos EB, Stathakis NE. Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus. Thromb Haemostas 1980; 44: 130-134
• 31 Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic retinopathy. Lancet 1989; i: 461-463
• 32 Ramsay RC, Goetz FC, Sutherland DER, Mauer SM, Robison LL, Cantrill HL, Knobloch WH, Najarian JS. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 208-204
• 33 KROC Colloborative Study Group Diabetic retinopathy after two years of intensified insulin treatment. JAMA 1988; 260: 37-41
• 34 Mangel WF. Enzyme systems – better reception for urokinase. Nature 1990; 344: 488-489
• 35 Goldfarb RH, Murano G, Brundage R, Siegal GP, Terranova V, Garbisa S, Liotta LA. Degradation of glycoprotein and collageneous components of the basement membrane: studies with urokinase-type plasminogen activator, alpha-thrombin and plasmin. Semin Thromb Hemostas 1986; 12: 335-336
• 36 Högemann B, Balleisen L, Rauterberg J, Voss B, Gerlach U. Basement membrane components (7S collagen, laminin P1) are increased in sera of diabetics and activate platelets in vitro. Haemostasis 1986; 16: 428-432
• 37 Triolo DE, Giardina E, Zarcone MR, Seddio G, Bompiani GD. Serum levels of type III procollagen peptide in diabetes mellitus. Horm Metab Res 1989; 21: 77-80